Mounjaro vs Ozempic — Which One Works Better?

Join Dr. Ben Synth as he breaks down the ultimate weight loss showdown: Mounjaro versus Ozempic. Discover which GLP-1 medication delivers superior results, from dramatic weight loss differences to cardiovascular benefits and side effects your doctor should discuss. Get the unfiltered science behind obesity medicine's biggest breakthrough drugs.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.

Join Ben Synth as he unpacks the SURMOUNT-5 trial's surprising tolerability data comparing Mounjaro (tirzepatide) to Ozempic (semaglutide). Discover why fewer patients quit the higher-dose medication, what quality-of-life metrics reveal beyond weight loss, and why adherence matters more than any number on the scale for long-term obesity treatment success.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.

Host Ben Synth examines the SURMOUNT-5 trial's overlooked findings beyond weight loss: tirzepatide versus semaglutide's impact on cardiovascular risk, quality of life, and long-term health outcomes. We discuss post-hoc analysis published in the European Heart Journal Open suggesting potential population-level differences in predicted heart attack and stroke prevention between these obesity medications.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.

Ben Synth examines SURMOUNT-5 trial results comparing tirzepatide to semaglutide for weight loss. The head-to-head study of 751 adults revealed tirzepatide achieved 20.2% average weight loss versus semaglutide's 13.7% over 72 weeks, marking a landmark moment in obesity pharmacotherapy and establishing dual-mechanism superiority.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.